Pharming Group N.V. ADS each representing 10 (PHAR)
$13.00
$0.04
(0.31%)
As on 15-May-2026 09:30EDT
Market cap
$892 Mln
Revenue (TTM)
$106,763 Mln
P/E Ratio
66.4
P/B Ratio
3.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
21.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
70,625,230
10 Years Aggregate
CFO
$264.39 Mln
EBITDA
$230.05 Mln
Net Profit
$-6.26 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Pharming Group N.V. ADS each representing 10 (PHAR)
| -26.4 | -26.5 | -15.7 | 42.1 | 5.4 | 1.4 | -- |
|
BSE Sensex
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Pharming Group N.V. ADS each representing 10 (PHAR)
| 75.6 | -11.9 | 3.6 | 23.4 | -41.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Pharming Group N.V. ADS each representing 10 (PHAR)
|
13.0 | 891.5 | 106,763.2 | 5,307.0 | 5.8 | 2147 | 66.4 | 3.4 |
| 813.3 | 50,825.9 | 5,779.3 | 1,830.5 | 8.7 | 27.3 | 36.1 | 6.6 | |
| 19.5 | 1,205.0 | 0.0 | -167.9 | -- | -128.7 | -- | 5.6 | |
| 106.9 | 10,398.1 | 6,066.4 | 609.2 | 18.3 | 16.7 | 17.9 | 4.2 | |
| 21.7 | 11,687.9 | 19,358.7 | 944.6 | 9.0 | 5.5 | 11.3 | 0.8 | |
| 27.5 | 1,862.3 | 1,043.8 | 488.8 | -19.0 | 16 | 3.2 | 0.5 | |
| 0.3 | 12.2 | 0.0 | -9.7 | -5,195.6 | -- | -- | 227.7 | |
| 3.0 | 585.2 | 3.2 | -198.4 | -4,800.7 | -166.3 | -- | 7.6 | |
| 6.5 | 338.7 | 0.8 | -75.0 | -6,681.4 | -- | -- | 6.7 | |
| 20.7 | 2,201.0 | 453.3 | -178.1 | -27.8 | -25.1 | -- | 3.2 |
Shareholding Pattern
View DetailsAbout Pharming Group N.V. ADS each representing 10 (PHAR)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is... RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. Address: Darwinweg 24, Leiden, Netherlands, 2333 CR Read more
-
President, CEO & Executive Director
Dr. Sijmen de Vries M.B.A., M.D.
-
President, CEO & Executive Director
Dr. Sijmen de Vries M.B.A., M.D.
-
Headquarters
Leiden
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Pharming Group N.V. ADS each representing 10 (PHAR)
What is the current share price of Pharming Group NV ADS each representing 10 (PHAR) Today?
The share price of Pharming Group NV ADS each representing 10 (PHAR) is $13.00 (NASDAQ) as of 15-May-2026 09:30 EDT. Pharming Group NV ADS each representing 10 (PHAR) has given a return of 5.44% in the last 3 years.
What is the current PB & PE ratio of Pharming Group NV ADS each representing 10 (PHAR)?
The P/E ratio of Pharming Group NV ADS each representing 10 (PHAR) is 66.44 times as on 12-May-2026.
The P/B ratio of Pharming Group NV ADS each representing 10 (PHAR) is 3.36 times as on 12-May-2026, a 35 discount to its peers’ median range of 5.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
463.55
|
4.78
|
|
2024
|
-67.15
|
3.60
|
|
2023
|
-79.10
|
3.81
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of Pharming Group NV ADS each representing 10 (PHAR)?
The 52-week high and low of Pharming Group NV ADS each representing 10 (PHAR) are Rs 21.34 and Rs 8.69 as of 15-May-2026.
What is the market cap of Pharming Group NV ADS each representing 10 (PHAR)?
Pharming Group NV ADS each representing 10 (PHAR) has a market capitalisation of $ 892 Mln as on 12-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Pharming Group NV ADS each representing 10 (PHAR)?
Before investing in Pharming Group NV ADS each representing 10 (PHAR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.